Clinical Trial

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To assess the efficacy and safety of Aumolertinib plus chemotherapy versus Aumolertinib alone as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor mutations (EGFRm+).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-06-10; most recent amendment 2024-11-21.
Status change: Recruiting → Active, Not Recruiting 2024-11-21
Status change: Not Yet Recruiting → Recruiting 2023-06-08
Trial Details
NCT Number NCT04923906
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Non-small Cell Lung Cancer
Enrollment 624 participants
Start Date 2021-08-11
Primary Completion 2024-06-18 (estimated)
Study Completion 2026-01-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-25